The positive predictive value (PPV) of the prostate biopsy—number of cancers found divided by the number of biopsies—when PSA was >3.0ng/ml was 48% in BRCA2 carriers, 33.3% in BRCA2 non-carriers, 37.5% in BRCA1 carriers and 23.3% in BRCA1 non-carriers. This evidence concerns the gene BRCA1 and cancer.